Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR | P11473 | 3/20 | 0.71 |
| ▸ | USP2 | O75604 | 1/20 | 0.71 |
| ▸ | ST6GAL1 | P15907 | 1/20 | 0.66 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.64 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | CASP7 | P55210 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22855501 | 0.93 | VDR (0.72) | VDRUSP2ST6GAL1ABCC4TP53 | |
| SCHEMBL22855103 | 0.93 | VDR (0.72) | VDRUSP2ST6GAL1ABCC4TP53 | |
| SCHEMBL22855112 | 0.93 | VDR (0.72) | VDRUSP2ST6GAL1ABCC4TP53 | |
| SCHEMBL22855053 | 0.93 | VDR (0.72) | VDRUSP2ST6GAL1ABCC4TP53 | |
| SCHEMBL22855058 | 0.92 | VDR (0.73) | VDRUSP2ST6GAL1ABCC4TP53 | |
| SCHEMBL22855082 | 0.89 | VDR (0.69) | VDRUSP2ST6GAL1ABCC4TP53 | |
| SCHEMBL22855089 | 0.87 | VDR (0.79) | VDRUSP2ST6GAL1ABCC4TP53 | |
| SCHEMBL2860648 | 0.87 | VDR (0.82) | VDRUSP2ST6GAL1ABCC4TP53 | |
| SCHEMBL2860645 | 0.87 | VDR (0.82) | VDRUSP2ST6GAL1ABCC4TP53 | |
| SCHEMBL13209452 | 0.87 | VDR (0.82) | VDRUSP2ST6GAL1ABCC4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020260558-A1 | 3-MODIFIED ISO-/ISOALLO-LITHOCHOLIC ACID DERIVATIVES OR THEIR HOMO-ANALOGS FOR PREVENTING AND TREATING CLOSTRIDIOIDES DIFFICILE-ASSOCIATED DISEASES | PHENEX PHARMACEUTICALS AG (DE) | 2020-12-30 | — | — | WO | disclosed |
| US-20160326086-A1 | 4-HYDROXYBUTYRIC ACID ANALOGS | SUN PHARMACEUTICAL INDUSTRIES, INC. | 2016-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160326086-A1 | 4-HYDROXYBUTYRIC ACID ANALOGS | HCRTR2, HCRTR1, HTR2B | VDR 2829/4885USP2 1927/4885ST6GAL1 2688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.